{"id":"W4411084855","doi":"10.1200/jco-25-00166","title":"Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bendamustine; Idelalisib; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ofatumumab; Gastroenterology; Clinical endpoint; Hazard ratio; Venetoclax; Ibrutinib; Leukemia; Lymphoma; Oncology; Confidence interval; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001527142,0.00125717,0.001775909,0.0003244581,0.0003707206,0.0007985321,0.0008030736,0.0008703073,0.005181974],"category_scores_gemma":[0.001115183,0.0004974747,0.001104161,0.0002877706,0.000791415,0.0006496459,0.0003823152,0.00214559,0.0009339329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000742296,"about_ca_system_score_gemma":0.00110824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007232277,"about_ca_topic_score_gemma":0.001838262,"domain_scores_codex":[0.9995486,0.0002473604,0.00002296978,0.00007950466,0.00003133333,0.00007010323],"domain_scores_gemma":[0.9993274,0.0001414832,0.0001315801,0.00004388441,0.00002950368,0.0003260623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9575531,0.007456115,0.001046708,0.0003025318,0.000531423,0.00006315244,0.00005730715,0.000584884,0.005457372,0.0001532309,0.001365733,0.02542836],"study_design_scores_gemma":[0.9086396,0.08657702,0.00201084,0.00002474098,0.0002819109,0.00007190672,0.00002213395,0.0007139407,0.0005687666,0.0001587952,0.0009192931,0.00001110083],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987152,0.002646475,0.0006762429,0.0005456744,0.0003481133,0.003343494,0.001316293,0.0001248046,0.003846898],"genre_scores_gemma":[0.9891027,0.001436547,0.001390166,0.0008475052,0.0003021223,0.002490218,0.001778474,0.00002369526,0.002628541],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005181974,"threshold_uncertainty_score":0.01733541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1296546004483546,"score_gpt":0.4747918773236469,"score_spread":0.3451372768752924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}